Endometrial cancer is the most common gynecological malignancy in the western world and its incidence is rising in tandem with obesity rates. When diagnosed early, the 5-year survival rate exceeds 90%. But when detected at advanced stages, survival falls below 20%. This dramatic difference makes early, accurate detection one of the most important problems in endometrial cancer medicine.
Current detection methods have significant limitations. Transvaginal ultrasound can measure endometrial thickness but has poor specificity - many benign conditions mimic cancer on ultrasound, leading to unnecessary further testing. Endometrial biopsy is the gold standard but is painful, has a high failure rate especially in certain patients, and can miss cancer in focal lesions. Hysteroscopy with biopsy is more accurate but expensive, painful, and carries rare but serious risks.
The ideal test would be simple, non-invasive, and accurately detect all cancers at the earliest stage with few false results. Such a test would be especially valuable for high-risk women, such as those with Lynch syndrome (an inherited condition that dramatically increases endometrial cancer risk), enabling surveillance without repeated invasive procedures. This review surveys the current state of proteomics-based biomarker discovery as a path toward this goal.
Several high-throughput molecular approaches have been explored for EC biomarker discovery, including genomics (studying DNA), transcriptomics (studying RNA), and proteomics (studying proteins). Each has strengths and limitations.
Genomic approaches are powerful for characterizing cancer mutations, but DNA sequencing cannot fully capture all disease-relevant processes because gene sequence alone does not determine how a cell behaves. mRNA levels (from transcriptomics) offer more dynamic information but do not correlate perfectly with protein levels - the actual functional molecules that carry out most biological activities in cells.
Proteomics - the large-scale study of all proteins in a biological sample - directly reflects what is happening functionally in cells and tissues. Proteins are the molecules that drive cellular activities, are secreted into body fluids, and can be measured using standard clinical assays like ELISA and immunohistochemistry. This makes proteins particularly well-suited for translation into clinical diagnostic tests that can be deployed in routine laboratory settings.
Mass spectrometry (MS) has become the core technology for discovering protein biomarkers. It identifies proteins by ionizing them and measuring the mass-to-charge ratio of their fragments, creating a molecular fingerprint. Modern MS instruments can detect and quantify thousands of proteins in a single run of a complex biological sample like blood or urine.
Two main MS approaches are used in biomarker discovery. The bottom-up (shotgun) approach digests proteins into peptides first, then analyzes the resulting fragments - enabling identification of thousands of proteins simultaneously. The data-independent acquisition (DIA/SWATH-MS) approach fragments every peptide in the sample rather than selecting the most abundant ones, increasing sensitivity and reproducibility, which is critical for detecting the low-abundance cancer-derived proteins expected in early-stage disease.
MALDI imaging (matrix-assisted laser desorption/ionization) offers a complementary approach for tissue-based studies: it creates protein maps of tissue sections that show where different proteins are located within the tumor, allowing correlation between molecular and architectural features visible under the microscope. Together, these technologies provide both comprehensive discovery of candidate biomarkers and validation in the clinical context where they would ultimately be used.
Blood is the most accessible biomarker source, but also the most challenging. Cancer-derived proteins circulate at very low concentrations in blood, diluted among thousands of abundant non-cancer proteins. Nevertheless, several promising candidates have been identified in serum and plasma, including hormones (prolactin, FSH), cancer antigens (CA125, HE4), adipokines (leptin, adiponectin), and various enzymes and growth factors.
The two most extensively studied blood-based EC biomarkers are HE4 (human epididymis protein 4) and CA125. HE4 shows a sensitivity of approximately 67% and specificity of 96% for EC detection; CA125 shows about 78% sensitivity and 61% specificity. Both are approved for monitoring treatment response but neither has sufficient accuracy for early detection screening. Combining them improves performance, but still falls short of clinical requirements.
A key problem with many reported blood biomarkers is that they reflect endometrial cancer risk factors rather than the cancer itself - particularly obesity and insulin resistance, which are so common in EC patients that biomarkers altered by these conditions appear to discriminate cancer from controls simply because the control groups are less obese. This confounding requires careful study design to avoid misleading results and may explain why many initially promising markers fail in larger validation studies.
Because cancer-derived signals are diluted in blood, biomarkers found in fluids closer to the tumor may offer higher sensitivity. Uterine lavage samples (saline flushed through the uterine cavity) contain proteins shed directly by endometrial tissue and have shown considerable promise as a higher-yield source for EC-specific biomarkers.
Cervical samples - obtained by the same brushing technique used for Pap smear cervical cancer screening - have also been explored. Because the uterine cavity is anatomically continuous with the cervical canal, cancer-derived cells and proteins may travel from the endometrium to the cervix. This raises the exciting possibility of screening for endometrial cancer at the same time as routine cervical cancer screening, using the same clinical visit.
Urine is perhaps the most accessible and patient-friendly sample type. Uterine proteins can appear in urine through various routes. Several studies have identified candidate protein biomarkers in urine samples from EC patients, and urine's low protein complexity compared to blood makes it a more tractable matrix for finding low-abundance cancer-specific signals. However, the reliability of uterine-to-urine biomarker transmission remains to be established.
The field of EC proteomic biomarker discovery is at a critical juncture. Many candidates have been identified in discovery studies, but few have been rigorously validated in independent, large-scale cohorts. Validation requires testing the same biomarker in samples from different hospitals, different patient populations, and ideally in prospectively collected samples where cancer was not yet diagnosed at the time of sampling.
The most promising future direction is multi-analyte panels that combine several protein biomarkers, and potentially integrate proteomics with genomic and metabolomic data. Single-protein markers are unlikely to achieve the sensitivity and specificity needed for population screening, but algorithmically combined multi-protein signatures may reach clinically meaningful performance thresholds.
Advanced technologies such as SWATH-MS enable the creation of permanent digital protein maps of biological samples that can be re-mined as new biomarker candidates are identified - a powerful feature for iterative validation. As detection methods mature and validation studies accumulate, proteomic biomarker tests for endometrial cancer could eventually enable non-invasive early detection, particularly for high-risk women with Lynch syndrome where current surveillance is both burdensome and imperfect.